Akoya Biosciences, Inc. (AKYA)
- Previous Close
2.1600 - Open
2.1900 - Bid 1.6000 x 200
- Ask 2.6800 x 200
- Day's Range
2.0900 - 2.2500 - 52 Week Range
1.8800 - 6.3100 - Volume
135,361 - Avg. Volume
153,348 - Market Cap (intraday)
105.074M - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1600 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.62
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
www.akoyabio.comRecent News: AKYA
View MorePerformance Overview: AKYA
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AKYA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AKYA
View MoreValuation Measures
Market Cap
107.06M
Enterprise Value
156.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.23
Price/Book (mrq)
7.85
Enterprise Value/Revenue
1.80
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.74%
Return on Assets (ttm)
-18.09%
Return on Equity (ttm)
-128.20%
Revenue (ttm)
93.22M
Net Income Avi to Common (ttm)
-60.35M
Diluted EPS (ttm)
-1.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
45.22M
Total Debt/Equity (mrq)
380.68%
Levered Free Cash Flow (ttm)
-34.91M